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Subtherapeutic erythropoietin and insulin-like growth factor-i correct
the anemia of chronic renal failure in the mouse. Chronic renal failure
(CRF) is associated with a hyporegenerative anemia, which is caused
primarily by inadequate production of erythropoietin (EPO) by the
diseased kidneys and is responsive to exogenous EPO administration.
Little is known about compensatory mechanisms that might supervene in
anemia with low levels of EPO. Multiple investigations in vitro suggest an
important role for insulin-like growth factor-i (IGF-i) as well as EPO in
erythropoiesis. Recently, both EPO and IGF-i in vitro have been found to
stimulate erythroid colony forming units in the mouse. However, no
studies have examined the effect of IGF-1, singly and in combination with
EPO, in CRF in vivo. This study examined mice with surgically-induced
renal failure of six weeks duration that were treated for three weeks with
the combination of subtherapeutic doses of both EPO and TGF-1. The
single administration of each cytokine caused no significant change in
hemoglobin in all CRF mice. In marked contrast the combined adminis-
tration of the two cytokines produced a striking rise in hemoglobin,
resulting in anemia correction in the majority of animals. The response to
the combination therapy was comparable to the maximal response ob-
tained with a single EPO dose (10 U) in a dose-finding study. Although the
data are limited to utilizing one dose of each cytokine and one preparation
of IGF-1, the large increase in hemoglobin observed with the combination
therapy indicates that these two cytokines work in concert to stimulate
erythroid precursors in CRF. In addition, untreated CRF mice showed
markedly increased serum levels of low molecular weight binding proteins
for IGF-1, potentially reducing the bioavailability of IGF-1. These findings
taken together suggest that the anemia of CRF may represent both an
EPO and a functional IGF-1 deficient state.
Chronic renal failure (CRF) is associated with a normochromic
normocytic anemia that is often multifactorial in origin. Etiologies
include decreased red cell survival, intramedullary hemolysis and
most commonly decreased erythropoietin (EPO) production. The
mainstay of therapy until recently included the use of red cell
transfusions combined with promoters of red cell production such
as androgens.
The advent of recombinant technology and the availability of
cytokines such as EPO has improved the management of patients
with end-stage renal disease and decreased the use of homologous
transfusion and its attendant risks [1—4]. in spite of the success of
EPO, the dose required can be variable and some patients require
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unusually large doses of this cytokine, suggesting that other
factors may play an important role in defining baseline erythro-
poiesis [5—7].
We have described two anephric patients on chronic hemodi-
alysis who maintained normal circulating levels of hemoglobin in
the absence of measurable EPO [8, 9]. When their plasma was
cocultured with allogenic marrow progenitors, a dose-dependent
number of erythroid colonies was formed. When EPO was added
to these cultures a further increase in the number of colonies was
observed. Following chromatography of their plasma, a low
molecular weight peptide was identified that also stimulated
marrow progenitors in vitro. Sequencing of this peptide identified
this activity as insulin-like growth factor-i (IGF-1). Although the
in vitro activity of IGF-1 in erythroid colony formation has long
been recognized [10—16], our finding of EPO-independent IGF-1
stimulation of red cells in these two patients suggested an
important human in vivo corollary.
We have recently investigated a murine model of CRF that
presents many of the features of CRF seen in the human including
expected biochemical abnormalities, immunological deficits, ath-
erosclerosis, osteodystrophy, and anemia despite the presence of
ample iron stores [17—26]. This animal model was used to further
define our results and more fully understand the role of IGF-1 in
erythropoiesis. We report that in the mouse with CRF, the
combination of subtherapeutic doses of EPO and IGF-1 causes a
significant rise in their hemoglobin level. This increase appears to
be comparable to that seen with the maximal single dose of EPO
(10 units) used in the study. This synergistic effect of these two
cytokines suggests that IGF-1 plays a major role in red cell genesis
during CRF.
Methods
Animals
All animal experimentation described in this paper was con-
ducted in accordance with the guidelines for the care and use of
experimental animals from the Canadian Council on Animal
Care. Female mice of the C57BL/6J inbred strain were purchased
at five weeks of age from Charles River Canada (St. Constant,
Quebec, Canada). The animals were used at eight to ten weeks of
age with a mean body wt of twenty grams. C57BL/6J mice have
been successfully used in our laboratory to induce a reproducible,
stable severe CRF in young adult mice [17, 21, 24]. Mice were
maintained under standard conditions of husbandry in the animal
facilities of McGill University. Groups of five mice were housed in
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shoe box plastic cages on wood shaving bedding with free access
to untreated tap water and regular mouse pellet diet. Mice
injected subcutaneously with IGF-1 received 5% glucose in their
water to eliminate the possibility of IGF-1 induced hypoglycemia.
Ear markings were used to permit rapid identification of all
animals. Mice were inspected daily for level of activity and
grooming, and appropriate healing of surgical wounds. Dead
animals were removed from the cages and the date of death
recorded. Autopsies were performed whenever possible.
Study design
In our initial experiments three groups of littermate animals
were selected: mice with renal failure of six weeks duration (CRF
group), normal control mice, and a phlebotomized cohort of mice
with normal renal function. Hematological and biochemical char-
acterization as well as circulating levels of IGF-1 and IGF-1
binding proteins were compared among the three groups of
animals. Following our initial results, only the CRF group was
studied and all cytokine injections reported in this study involved
only those animals with CRF.
Induction of renal failure
After a one-week acclimatization period in our facilities, renal
failure was induced surgically in the mice according to previously
described procedures [171. Electrocoagulation of the surface of
the right kidney was first performed, followed by left nephrectomy
two weeks later. The right kidney was approached through a 2-cm
long skin incision in the right flank. Following exposure, the
kidney was freed from the perirenal fat and adrenal gland by fine
tissue dissection and brought up to the skin surface. Using a
foot-operated single point cauterizer (Hyfrecator, Model X-712;
The Birtcher Corp., Los Angeles, CA, USA) angled at 300, the
entire surface of the kidney was electrocoagulated except for a 2
mm rim of intact tissue around the hilum. After the electrocoag-
ulation, the kidney was guided back into the renal fossa. Great
care was taken to avoid damage to the ureter from either direct
trauma or elongation/distortion during mobilization of the kidney.
The deep layer of the surgical wound was closed with a running
suture using 5-0 silk, and stainless steel surgical autoclips were
applied to the skin. A left nephrectomy was performed two weeks
later. The left kidney was exposed through the left flank as
described for the right kidney and the vascular pedicle was ligated
at the hilum using 6-0 silk. Vascular tissue was sectioned distal to
the suture and the kidney was removed. The surgical wound was
closed as above. Anesthesia was provided by atropine sulfate
given s.c. in the nape of the neck (0.03 mg/kg) followed by an i.p.
injection of ketamine (150 mg/kg) and xylazine (7.5 mg/kg). The
skin clips were removed two weeks after each procedure. The time
of the left ncphrectomy marked the onset of the renal failure. The
degree of renal failure was confirmed by measurement of serum
urea one week following the left nephrectomy.
Induction of acute anemia
Anemia was induced acutely in normal mice by controlled
blood letting under general anesthesia using methoxyflurane.
Using a capillary tube, a small volume of blood (0.4 ml) was
collected from the retro-orbital venous plexus. This procedure
was repeated on three successive days. The phiehotomized mice
were studied on the fourth day at the time of sacrifice. In
Table 1. Experimental design
Time (weeks) Procedure
0 Electrocoagulation of the surface of the right kidney
2 Left nephrectomy (time of onset of renal failure)
5 Determination of hemoglobin concentration
5—8 Treatment with cytokines singly and in combination by
thrice weekly injections
8 Sacrifice-evaluation
preliminary studies this approach was shown to induce a repro-
ducible severe anemia.
Treatment with EPO and/or insulin-like growth factor-I
Details of the experimental protocol involving treatment of
CRF mice with cytokines are presented in Table 1. A commercial
injectable formulation of recombinant human EPO (Eprex, lot
number 636067; Ortho McNeil, Toronto, Canada) was used. The
stock solution in PBS contained 4000 U/ml of EPO. The dose of
EPO used in this study was chosen from previous studies in the rat
and adjusted for the smaller body wt of mice [28, 291. IGF-1 was
a commercial preparation of IGF-1 (lot number BJB AOl;
GroPep, Adelaide, Australia). This long R3 IGF-1 was rehydrated
in PBS achieving a stock solution of 1 mg/mI. This dose was
chosen based on results derived from the hypophysectomised rat
model which incorporates 59Fe into erythrocytes and develops
reticulocytosis following IGF-1 stimulation [341. The dose was
adjusted for the weight of our mouse cohorts. All animals of a
given experiment received the same total volume of PBS for both
cytokines. In all treatment experiments, the cytokines were given
to the mice starting three weeks after the onset of renal failure
(time of left nephrectomy). Before treatment, the animals were
bled to determine their hemoglobin levels. The animals were
injected three times per week for three weeks either i.p. (dose-
response to EPO experiment) or s.c. in the nape of the neck (EPO
and IGF-1 treatment experiment).
Peripheral blood collection
Blood was drawn from the retro-orbital venous plexus or lateral
tail vein using a heparinized Pasteur pipette.
Hemoglobin concentration and reticulocyte count
Because of the small volumes of blood obtained, a quantitative
colorimetric assay was used to measure hemoglobin levels. Levels
of cyanmethemoglobin were measured using a spectrophotomet-
nc method according to the manufacturer's recommendations
(StanBio hemoglobin procedure, #0320, 0321, 0325; StanBio
Laboratory mc, San Antonio, TX, USA). Circulating reticulocytes
were enumerated on thick blood smears freshly prepared on glass
slides and stained with brilliant cresyl blue.
Serum urea levels
The urea was calculated using the Kodak Ektachem DT slide
method according to the manufacturer's recommendations
(Kodak Ektachem DT slide method, DT 60 II Analyzer; Roches-
ter, NY, USA).
Senim EPO levels
The serum EPO level was measured using a commercial
radioimmunoassay kit (EPO DSL cat #1100; Webster, TX, USA).
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Measurements in duplicate were made following manufacturer's
recommendations.
Western ligand blotting for IGF-1 binding proteins
Western ligand blotting was performed by the following meth-
od: 10 jxl of sera was diluted in 20 ,uJ PBS buffer and 20 j.d
sodium-dodecyl-sulfate (SDS)-sample buffer without added re-
ducing agent. The sample was heated at 95°C for five minutes, and
electrophoresed in 12.5% SDS-polyacrylamide (mini-gel, Bio-
Rad). The separated proteins were transferred by wet-blotting
(Trans-blot, Bio-Rad) to nitrocellulose membranes (Millipore) at
30 volts overnight in transfer buffer (0.02 mol/liter Trizma base
and 0.2 mol/liter glycine in 20% methanol—50% distilled water).
Membranes were blocked for two hours at 4°C with 4% milk
powder with 0.1% NP-40 (non-ionic detergent) to occupy non-
specific binding sites. Membranes were then incubated overnight
with '251-IGF-1, washed extensively with PBS buffer, air-dried and
exposed to autoradiographic film for two days.
Serum IGF- I levels
Serum IGF-1 levels were measured by direct radioimmunoassay
without extraction following published procedures [271. Extrac-
tion was not performed because of the low levels of binding
protein 3 found in our samples. The RIA used antiserum UBK487
provided by the National Pituitary Agency (NIAMDD), courtesy
of Dr. L. Underwood and Dr. J.J. Van Wyk. This antiserum has a
0.5% cross-reactivity with IGF-2 and no cross-reactivity with
insulin at 10 M. Recombinant human IGF-1 obtained from Eli
Lilly (Indianapolis, IN, USA) was used as a standard. Standard
and serum samples at three separate dilutions (1:200, 1:400 and
1:800) were incubated in duplicate with antibody (1:18,000 final
dilution) two hours at room temperature before addition of
radiolabeled IGF-1. After overnight incubation, antibody-bound
radiolabeled IGF-1 was precipitated using goat anti-rabbit gamma
globulin and normal rabbit serum as a carrier.
Statistical analysis
Results are presented as the means SD. Data from the initial
characterization experiments were analyzed by paired t test, and
data from the cytokine treatment experiments were subjected to
analysis of variance and unpaired t test for multiple intergroup
comparisons. The P values < 0.05 were considered to be statisti-
cally significant.
Results
Selected characteristics of CRF mice
Selected biochemical and hematological characteristics of 13-
week-old female inbred C57BL/6J mice six weeks after the
surgical induction of renal failure are shown in Table 2. The mean
serum urea concentration of CRF mice was approximately five
times normal, indicating severe impairment of renal function.
Compared to normal control littermates, the CRF mice presented
a moderate anemia with unchanged circulating reticulocyte count
and serum EPO level; the serum IGF-l level in these mice was
also unchanged. These results were significantly different from
those of littermate mice with normal renal function made severely
anemic by acute bleeding. In these control phlebotomized mice
the expected marked increases in circulating reticulocyte count
(6-fold) and serum EPO level (20-fold) were observed. Further-
Table 2. Selected characteristics of mice with chronic renal failure
Renal failure Normal Phlebotomy
Parameters N = 18 N = 16 N = 15
Body weight g 19.1 1.9° 20.4 1.5 18.7 1.3'
Urea mmol/liter 32.8 8.7" 6.7 1.3 5.9 1.0
Hemoglobin g/liter 91 15" 145 5 57 8'
Reticulocytes % 1.6 0.8 1.7 0.7 10.4 1.6"
EPO mU/mi 10 10 14 16 307 60"
IGF-1 ng/ml 225 57 271 78 164 64"
Total protein gIlder 55.8 3.9 51.4 4.9 50.9 3.8
Albumin g/iiter 31.0 1.3 29.0 1.0 29.5 1.0
Results of biochemical and hematological testing in 13-week-old female
inbred C57BL/6J mice at sacrifice 6 weeks after the onset of renal failure
compared with normal and acutely bled control littermates in the center
and right columns, respectively. Details of the surgical mode of induction
of renal failure and of the phlebotomy procedure are given in the Methods
section. Data are expressed as mean SD. Significant differences (P <
0.05) between "renal failure and normal mice and between hphlehoto
mized and normal mice.
more, the serum IGF-1 level of these mice was significantly
reduced, possibly reflecting the marked stress of the acute anemic
state. The body weights of both CRF and phlebotomized mice
were significantly lower than normal. No significant change was
observed in the serum concentrations of total protein and albumin
of the two anemic mouse groups.
Determination of serum IGF-1 binding proteins in CRFmice
Figure 1 shows the Western blot analysis of serum IGF-l
binding proteins 1, 2 and 3 for the three mouse groups. Equal
amounts of serum (10 ,al) from CRF, normal and phlebotomized
mice, as well as from rat and human controls, were applied in each
lane. Shown on the left lane are reference protein markers for 21,
31, 45, 66 and 92 kDs; the expected location for IGFBP-1,
IGFBP-2 and IGFBP-3 is indicated on the right. The data
indicated that the concentration of IGFBP-3 in the sera of all mice
was only faintly detectable compared to normal rat and human.
The concentrations of IGFBP-1, and more particularly of
IGFBP-2, were significantly increased in the serum of CRF mice,
resulting in a marked rise in the ratios of IGFBP-1 and IGFBP-2
to IGFBP-3.
Effect of EPO treatment on the anemia of CRF mice
To determine the therapeutic effect of EPO on the anemia of
CRF mice, we examined the effect of a range of EPO doses based
on previously reported data in rats [28, 291. The treatment with
EPO was begun three weeks after the onset of renal failure when
the anemia was well established, in thrice weekly intraperitoneal
injections during three weeks (Table 1). All CRF mice had
comparable degrees of anemia at the start of treatment (Table 3).
The anemia of control untreated CRF mice (saline injections
only) was unchanged over the three week period (Fig. 2). Treat-
ment with low dose EPO (1 and 2 units) failed to correct the
anemia, except for one mouse of the 2 unit group (Hb concen-
tration > 135 g/liter). In marked contrast, treatment with the
higher EPO doses (5 and 10 units) resulted in full correction of
the anemia in the majority of mice (4 out of 5) of each group. No
difference was observed between the groups receiving the 5 and 10
unit EPO doses. This experiment establishes the 2 unit EPO dose
as a subtherapeutic dose in correcting the anemia of CRF mice.
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None 7 108 15 107 17 —1 1
1 unit 7 114 17 112 21 —2 7
2 units 8 112 12 116 20 +4 13
5 units 5 104 25 139 20 +36 17k'
10 units 5 103 16 136 23' +32 14
Three-week treatment with EPO starting 3 weeks after the onset of
renal failure consisted in thrice weekly intraperitoneal injections of 1, 2, 5,
and 10 units of EPO in a final volume of 0.4 ml sterile saline. Control
untreated CRF mice received saline injections only. The baseline hemo-
globin (Hb) concentrations were not statistically different between the
groups. The change in Hb concentration at the end of the 3-week
treatment period is presented in percent values. Data are expressed as
mean SD. Significant differences (P < 0.05) between atreated and
untreated CRF mice.
____
Fig. 1. Determination of serum IGF-1 binding
BP3 proteins in mice with CRF: Western blot. IGF-1
binding proteins 1, 2 and 3 in the serum of
CRF, normal and phlebotomized mice were
____
compared to normal rat and human. A
BP2 representative analysis after two days exposure
with reading from left to right is: lane 1,
E BP1 protein markers (MW); lanes 2 and 3, normalmice (N7, N8); lanes 4 and 5, phlebotomized
mice (P9, P10); lanes 6 and 7, CRF mice (Cli,
C12); lane 8, normal rat (RAT); and lane 9,
normal human (HUM).
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Effect of treatment with subtherapeutic EPO and IGF-1 on the
anemia of CRF mice
To determine the synergy of EPO and IGF-1 in the treatment
of the anemia of CRF mice, we examined the effect of combining
subtherapeutic IGF-l 2.4 g with the subtherapeutic 2 unit EPO
dose. In this Set of experiments, treatment with the two cytokines
was begun three weeks after the onset of renal failure in thrice
weekly subcutaneous injections during three weeks (Table 1). All
CRF mice have comparable anemia at the start of the treatment
period (Table 4). Again, the anemia of control untreated CRF
mice receiving injection of the vehicle only (sterile saline) is
unchanged three weeks later (Fig. 3). As expected, no significant
response is observed in the animals receiving EPO alone (2 unit
dose). Similarly, there was no significant difference in the hemo-
globin concentration of the mice treated with IGF-l alone at the
chosen dosage of 2.4 jg (Fig. 3). The combined treatment with
EPO and IGF-1 significantly increases the hemoglobin concentra-
tion in all CRF mice with a mean 50% increase from pretreatment
EPO dosage, unit per mouse
Fig. 2. Effect of EPO treatment on the anemia of mice with CRF: %
hemoglobin change. Three week treatment with EPO starting three weeks
after the onset of renal failure consisted of thrice weekly intraperitoneal
injections of 1, 2, 5, and 10 units of EPO in a final volume of 0.4 ml sterile
saline. Control untreated CRF mice shown on the left received saline
injections only. Salient characteristics of the CRF mice are given in the
legend to Table 2. The baseline hemoglobin concentrations were not
statistically different between the groups (Table 3). Data represent the
percent change in hemoglobin concentration at the end of the three-week
treatment period, Individual data shown with means indicated by horizon-
tal bars. Significant differences (P < 0.05) between *treated and untreated
CRF mice.
values. This marked effect of the combined treatment achieves full
correction of the anemia in the majority of CRF mice (7 of 11).
This experiment establishes the combination of subtherapeutic
EPO and IGF-1 as a synergistic treatment of the anemia of CRF
mice.
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Table 4. Response of the anemia of CRF mice to treatment with
subtherapeutic EPO and IGF-1 used alone and in combination
Treatment Baseline Hb Final Hb Change in
modality N giliter g/liter Hb %
No cytokine 8
EPO alone, 2 units
IGF-1 alone, 2.4
.rg
8
7
Combined EPO + IGF-1 11
107±11 107±19 —1±9
102±5 99±4 —3±6
100±16 98±13 —2±11
94 13 140 13 +50 8
Three week treatment with EPO and IGF-1 starting 3 weeks after the
onset of renal failure consisted in thrice weekly subcutaneous injections of
2 units of EPO and 2.4 jg of IGF-1, used singly and in combination, in a
final volume of 0.1 ml sterile saline. Control untreated CRF mice received
saline injections only. The baseline hemoglobin (Hb) concentrations were
not statistically different between the groups. The change in Hb concen-
tration at the end of the 3-week treatment period is presented in percent
values. Data expressed as mean SD. Significant differences (P < 0.05)
between treated and untreated CRF mice.
Discussion
Erythropoiesis involves different cytokines and their interaction
with erythroid marrow progenitors [5—7, 14, 30—33]. A wealth of
knowledge exists on the role of EPO in erythropoiesis in vitro, and
recent accumulating evidence suggests a similar role for IGF-1 [6,
10—151. IGF-1 is able to prevent apoptosis of erythroid progeni-
tors and exerts a proliferative effect on late erythroid precursors.
The administration of IGF-1 to hypophysectomized rats results in
red cell 59Fe incorporation and an increased reticulocyte count
[34}. This effect is both indirect by increasing the level of EPO,
and direct by stimulating erythropoiesis before a demonstrable
rise in EPO level. Normal adult mice have also been shown to
increase their reticulocyte counts when repeatedly injected with
IGF-1 [35]. These limited data suggest an erythropoietic activity
for IGF-1 in vivo, however, no actual increases in hemoglobin
concentration have been documented to date. Previous results
from our laboratory suggest that peptides such as IGF-1 are
important for regulation of erythropoiesis during CRF [8, 9].
More recently we have demonstrated that the liver and bone
marrow of CRF mice do not express EPO message as assessed by
RT-PCR [361. This absence of extrarenal EPO production raises
the possibility that IGF-1, an erythrogenic peptide, may compen-
sate for the decreased renal production of EPO in this model.
The present study was undertaken following our previous
observations in two anephric patients on maintenance hemodial-
ysis with normal hemoglobin concentrations and our recent
findings of absent extrarenal expression of EPO in the liver and
bone marrow of our murine CRF model. The two patients
maintained normal hemoglobin levels despite undetectable levels
of EPO. When their plasma was plated with allogeneic hone
marrow progenitors, a dose-dependent increase in erythroid
colony forming units was obtained. Addition of EPO to these
cultures increased the colonies in an additive fashion. Following
high-pressure liquid chromatography and sequencing of the pa-
tients' plasma, this activity was identified as IGF-l [91. This
observation represents the first human in vivo evidence suggesting
an effect of this peptide in improving the anemia of CRF. We have
extended these data to a murine model of CRF to further
characterize the possible role of IGF-1 on erythropoiesis.
The animal model utilized in this study bears many similarities
with its human counterpart including the retention of nitrogenous
wastes, abnormalities in electrolytes and acid-base status, hyper-
Treatment modality
S
1'S. *
Fig. 3. Effect of treatment with subtherapeutic doses of EPO and IGF-1 on
the anemia of mice with CRF: % hemoglobin change. Three week treatment
with EPO and IGF-1 starting three weeks after the onset of renal failure
consisted in thrice weekly subcutaneous injections of 2 units of EPO and
2.4 j.g of IGF-1, used singly and in combination, in a final volume of 0.1
ml sterile saline. Control untreated CRF mice shown on the left received
saline injections only. Salient characteristics of the CRF mice are given in
the legend to Table 2. The baseline hemoglobin concentrations were not
statistically different between the groups (Table 4). Data represent the
percent change in hemoglobin concentration at the end of the three-week
treatment period. Individual data shown with means indicated by horizon-
tal bars. Significant differences (P < 0.05) between* treated and untreated
CRF mice.
cholesterolemia with atherosclerosis in defined mouse strains such
as the C57BL/6J strain, extensive bone disease, susceptibility to
infection, and a normochromic normocytic anemia correlating
with the degree of renal impairment [17, 21, 24]. There are many
particular advantages of this mouse model over existing models of
CRF: (1) the mode of induction of renal failure is rapid and
straightforward with no evidence of local and systemic surgically-
related complications; (2) the CRF mice can be maintained easily
under standard measures of animal husbandry even when the
renal failure is severe; (3) the degree of the electrocoagulation to
the right kidney determines the magnitude of the renal failure
which remains stable over time, thereby enabling the conduct of
long-term experiments; (4) there is a wide array of biological
reagents available for studies in the mouse which has been the
preferred animal species for the investigation of non renal ane-
mias of various etiology. Furthermore, the recent availability of
assays requiring smaller blood volumes have facilitated studies in
the mouse. The results of our studies clearly validate the extreme
sensitivity, reproductibility, and value of the mouse model for the
study of the regulation of erythropoiesis in the anemia of CRF.
A key feature of this model is the predictable response of the
CRF mice to treatment with recombinant EPO. We have shown
that CRF mice display consistently a maximal response to the
EPO dose of 5 U/three times/week, whereas the lower dosage of
the cytokine (2 U/three times/week) is ineffective in stimulating
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erythropoiesis. The hematopoietic response of the CRF mice to
EPO treatment strongly suggests an S-shaped biological curve.
The lack of response to low doses of EPO (1 and 2 units) suggests
the presence of a biological mechanism that triggers erythropoi-
esis only when the appropriate level is reached. The absence of a
further increase in the response by increasing the EPO dosage
from 5 to 10 units suggests that physiological saturation has
occurred. Thus, any attempt to further increase the hemoglobin
concentration with increasing EPO doses would likely result in
great cost, yet little therapeutic gain.
Probably the most important finding in this study relates to the
use of subtherapeutic doses of both EPO and IGF-1 in combina-
tion to treat the anemia of CRF. Studies of the two cytokines used
singly at the chosen dosage (EPO 2 units, IGF-1 2.4 j.tg) reveal no
change in hemoglobin values after three weeks of treatment. In
marked contrast, combination treatment with the two cytokines at
the same dosage significantly increases the hemoglobin of all CRF
animals, indicating a clear synergistic effect on erythropoiesis. It is
noteworthy that the results with the combination therapy are
comparable to those obtained with the maximal single dose of
EPO (10 units) used in the dose-finding study. Furthermore, all
animals respond in a rapid fashion with significant responses
already observed after only one week of treatment (data not
shown).
Although the response to this combination of factors is encour-
aging, the mechanisms underlying this synergy remain elusive.
Because the mouse with CRF has an inappropriately low level of
EPO for the degree of anemia, we initially expected to find a
reciprocal increase in the serum level of IGF-1. However, IGF-1
levels were not significantly increased when compared to normal
littermates (Table 2). This observation is corroborated by recent
studies in children with renal failure given growth hormone whose
IGF-1 levels were similar to controls [37, 38]. Since the levels of
EPO in the CRF mice were not increased and IGF-1 levels were
similar to those of controls, we raised the possibility of a state of
somatomedin inhibition in our renal cohort. This state of somato-
medin inhibition in renal failure would arise from the presence of
increased circulating levels of low molecular weight binding
proteins [39—43], decreasing the amount of functional or bioavail-
able IGF-1. Two different mechanisms have been proposed to
increase this pool of growth hormone independent low molecular
weight inhibitors in renal disease. Firstly, decreased insulin levels
and the growth hormone resistant state seen in renal disease
increase the concentration of BP1, a low molecular binding
protein in the circulation. Secondly, disaggregation of large
molecular weight binding proteins such as BP3 by proteases
provides a further pool of smaller binding proteins [40]. Such
candidate proteases have been identified in the urine of patients
with renal failure [44]. This pooi of low molecular weight binding
proteins for IGF-1 are active as somatomedin inhibitors and serve
to modulate IGF-1 function [37, 38, 42, 43].
Our animals with CRF have increased circulating concentra-
tions of low molecular weight binding proteins that can act as
somatomedin inhibitors (Fig. 1). We therefore postulated that a
functional state of IGF-i depletion might exist during CRF and
that the anemia of CRF represents both an EPO and IGF-1-
deficient state. Our results following the combined administration
of EPO and IGF-1 are at least in part due to the replacement of
IGF-I. Alternatively, the pre-pro IGF-i preparation utilized in
these experiments, with known decreased binding protein affinity,
may provide a larger pool of free IGF-1 available for interaction
with its receptor. This mechanism resembles that seen with
mutant IGFs which bind poorly to the binding proteins and
consequently have increased biological activity [45, 461.
In conclusion, our results show that the combination of sub-
therapeutic doses of EPO and IGF-1 increases the hematocrit in
mice with CRF. These interesting results notwithstanding, we are
unable at the present time to explain the synergistic interaction
between EPO and IGF-1. The presence of IGF-1 receptors on
erythroid precursors [12, 32] and the ability of IGF-i in vitro to
stimulate erythroid progenitors despite the presence of EPO
suggest that IGF-1 likely mediates its effect through its own
separate receptor. A previous publication from our group re-
vealed a dose effect relationship between the concentration of
anephric patient plasma and the number of in vitro erythroid
colonies [8]. This stimulatory activity, subsequently defined as
IGF-1, was further augmented by the addition of EPO, lending
further support to a two receptor model to explain our results.
Although the mechanism of this interaction is unclear, both
proteins are known to prevent apoptosis of erythroid precursors
and IGF-1 has known mitogenic potential for late erythroid
precursors. Thus both proteins might work in concert to prevent
apoptosis and/or increase the number of late erythroid precursors
available for maturation.
To our knowledge, the synergistic effect of the combination of
subtherapeutic EPO and IGF-1 is the first in vivo demonstration
of a role for IGF-1 in the treatment of anemia in CRF. Our study
suggests that combination therapy with EPO and IGF-1 may
represent a novel and effective approach to the management of
CRF associated anemia. From a practical standpoint, our results
suggest that the occasional patient with end-stage renal disease
not responding to large doses of EPO might be a candidate for
combination therapy with these cytokines. Alternatively, the use
of lower doses of each cytokine may decrease the current cost of
EPO treatment for a significant number of patients. Further
studies are presently underway to address these issues.
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